By 2026, Europe’s psychedelic medicine story was no longer hypothetical.

The Czech Republic has created a legal framework for therapeutic psilocybin. Germany has opened the EU’s first compassionate-use programme for psilocybin, with access now available in regulated centres in Mannheim and Berlin. The European Medicines Agency is still working through how psychedelic trials should be designed and evaluated. Pharma is watching. Capital is circling.

European psychedelic medicine is no longer a someday story. It is happening now, in regulatory filings, clinic rooms, trial protocols, and term sheets.

And there is still no single sober place to follow it.

That is the gap Psychedelic Brief exists to fill.

Most serious coverage of this field is still written for an American reader. That makes sense. The FDA has issued formal guidance, capital is deeper in the US, and the loudest companies have often been funded, listed, or followed through an American lens.

But Europe is not a smaller version of the US market. It is a different animal.

Clinical trials now run through a single EU entry point, CTIS. But that is where the harmonisation stops. Pricing, reimbursement, and access stay separate national battles. A treatment can clear the science and still hit a wall.

The EU’s HTA framework may improve coordination, but it does not eliminate the national battles that determine whether patients actually receive treatment.

That is where the business of access begins.  

If you want to understand where psychedelic medicine is actually going in Europe, you need someone watching Europe specifically. Weekly. That is the job.

One email, every Tuesday at 8 am CET. Clinical trial readouts that matter. Financings and the people behind them. Regulatory moves from the EMA and national agencies across the EU, plus the MHRA in the UK. The occasional piece of data is worth more than the ten headlines around it.

Each issue is written to be read in the time it takes to finish a coffee, and to leave you knowing something you did not know before. I will tell you what a development means, not just that it happened.

No hype. The breathless “psychedelics will cure everything” register does this field no favours, and I will not write in it.

No retreat ads. I am not here to sell you a week in the jungle. This is about medicine, regulation, and the business being built around them.

No trip reports. There are better writers for the inner experience of psychedelics. Psychedelic Brief is an intelligence briefing, not a consciousness diary.

If a story is boring but important, you’ll get it. If a story is exciting but empty, you won’t.

I built the briefing I wanted to read and could not find.

I’m an operator who got close to this sector, kept seeing the same gap, and decided to fill it properly: Europe-first, source-driven, and commercially serious. I will get things wrong sometimes, and when I do, I’ll correct them in the open.

You can also reply to any issue, and a human will read it. Tell me what I am missing. That is not a marketing line; it is part of the product.

The default source of truth for European psychedelic medicine.

No hype. No retreat ads. Just signal.

Every Tuesday. 8am CET. Free to read.

Subscribe below. I’ll see you in the first issue.